Furthermore, PPARγ ligand pioglitazone is recommended for selected NAFLD patients by the European‐ and American Association Guideline for the Study of the Liver.118, 119. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.